Fusion Competitors

Delisted . USA . 
Stock . Fusion Pharmaceuticals
FUSNDelisted Stock  USD 3.75  0.33  8.09%   
Fusion Pharmaceuticals competes with Bicycle Therapeutics, Relmada Therapeutics, RAPT Therapeutics, NewAmsterdam Pharma, and Bioatla; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Fusion Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Fusion Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Fusion Pharmaceuticals competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Fusion Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
3.753.753.75
Details
Intrinsic
Valuation
LowRealHigh
3.523.524.13
Details
Naive
Forecast
LowNextHigh
3.793.793.79
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
3.714.475.24
Details

Fusion Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Fusion Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Fusion and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Fusion Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
SPRO
+ 0.75
OLMA
OLMA
+ 0.7
RAPT
OLMA
+ 0.67
BCYC
PMVP
+ 0.66
NAMS
SPRO
+ 0.65
RAPT
BCAB
+ 0.62
RAPT
  
High negative correlations   
OLMA
- 0.49
NAMS
SPRO
- 0.47
NAMS
PASG
- 0.38
NAMS
NAMS
- 0.29
RAPT
PASG
- 0.2
RLMD
NAMS
- 0.2
BCYC

Risk-Adjusted Indicators

There is a big difference between Fusion Stock performing well and Fusion Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Fusion Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
BCYC  2.34 (0.26) 0.00 (0.03) 0.00 
 0.00 
 4.68 
(3.70)
 35.92 
RLMD  2.73  0.18  0.06  0.31  2.64 
(3.21)
 7.47 
(4.75)
 21.75 
RAPT  5.64 (0.88) 0.00 (0.18) 0.00 
 0.00 
 10.00 
(11.56)
 61.07 
NAMS  2.35  0.07  0.06  0.16  3.39 
(2.63)
 5.33 
(4.57)
 29.23 
BCAB  4.44 (0.13)(0.01) 0.04  4.78 
(5.50)
 12.86 
(7.59)
 31.41 
PASG  6.16  0.76  0.15  0.37  5.91 
(7.95)
 12.07 
(10.45)
 32.24 
PMVP  1.56 (0.03)(0.03) 0.08  1.99 
(1.90)
 3.75 
(3.64)
 13.98 
IKNA  0.93 (0.08) 0.00 (0.02) 0.00 
 0.00 
 1.81 
(1.74)
 5.87 
OLMA  2.88 (0.41) 0.00 (0.05) 0.00 
 0.00 
 6.17 
(5.89)
 19.19 
SPRO  1.77 (0.32) 0.00 (0.57) 0.00 
 0.00 
 3.79 
(4.58)
 14.92 
All Fundamental Data

Fusion Pharmaceuticals Competitive Analysis

The better you understand Fusion Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Fusion Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Fusion Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
FUSN BCYC RLMD RAPT NAMS BCAB PASG PMVP IKNA OLMA
 8.09 
 3.75 
Fusion
 0.25 
 20.40 
Bicycle
 4.14 
 3.02 
Relmada
 2.44 
 1.26 
RAPT
 4.57 
 19.85 
NewAmsterdam
 2.44 
 1.68 
Bioatla
 68.66 
 1.13 
Passage
 1.25 
 1.62 
Pmv
 2.37 
 1.73 
Ikena
 4.12 
 10.12 
Olema
Market Volatility
(90 Days Market Risk)
Very steady
Not too volatile
Very risky
Moderately volatile
Not too volatile
Dangerous
Out of control
Slightly risky
Relatively risky
Slightly risky
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Insignificant
Very Weak
OK
Very Weak
OK
Weak
Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Low
Above Average
Above Average
About Average
Low
Quite High
Average
Average
Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Hold
Strong Sell
Cautious Hold
Cautious Hold
Strong Sell
Cautious Hold
Cautious Hold
Hold
Sell
Current Ratio
17.89
9.88
11.4
15.97
N/A
7.48
9.23
24.76
6.98
19.75
Net Asset
285.84 M
595.34 M
97.55 M
173.33 M
347.1 M
119.66 M
150.54 M
252.15 M
192.09 M
276.94 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(97.89 M)
(183.4 M)
4.91 M
(125.85 M)
(176.86 M)
(122.24 M)
(98.34 M)
(78.88 M)
(74.4 M)
(104.58 M)
Operating Margin
-54.04
-23.86
N/A
N/A
-0.86
-1.02
N/A
N/A
-97.55
N/A
Current Valuation
1.69 B
528.76 M
37.01 M
(48.74 M)
1.41 B
24.7 M
10.79 M
(85.74 M)
(46.15 M)
366.79 M
Price To Book
8.13
1.69
1.91
0.46
4.84
3.54
0.96
0.42
0.62
2.92
Retained Earnings
(376.76 M)
(511.76 M)
(560.9 M)
(484.68 M)
(316.97 M)
(416.26 M)
(594.47 M)
(310 M)
(282.38 M)
(305.63 M)
Current Asset
N/A
103.53 M
9.3 M
17 K
N/A
N/A
144.91 M
N/A
N/A
N/A
Beta
-0.69
0.89
0.42
0.32
-0.001
1.02
1.2
1.48
0.49
2.03
Number Of Employees
101
284
20
70
62
65
58
63
14
74
Shares Outstanding
85.06 M
47.55 M
30.17 M
34.96 M
92.39 M
48.35 M
61.77 M
51.75 M
48.26 M
57.3 M
Cash Flow From Operations
(81.8 M)
(60.63 M)
(51.66 M)
(97.05 M)
(141.22 M)
(104.02 M)
(78.26 M)
(55.66 M)
(79.74 M)
(83.73 M)
Total Debt
50.33 M
44.96 M
12.19 M
6.91 M
60 K
2.46 M
26.29 M
13.29 M
10.74 M
2.42 M
Return On Equity
-0.47
-0.27
-1.0
-0.8
-0.47
-1.39
-0.64
-0.24
-0.37
-0.52
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.23
-0.15
-0.59
-0.47
-0.29
-0.5
-0.34
-0.2
-0.22
-0.32
Number Of Shares Shorted
3.06 M
3.52 M
1.15 M
1.66 M
1.01 M
4.14 M
1.63 M
846.9 K
82.56 K
8.56 M
Book Value Per Share
2.85
12.04
2.84
2.74
4.11
0.48
2.03
3.82
2.78
3.47
Current Liabilities
N/A
8.46 M
3.06 M
167 K
N/A
N/A
3.09 M
N/A
N/A
N/A
Total Asset
285.84 M
595.34 M
97.55 M
173.33 M
347.1 M
119.66 M
150.54 M
252.15 M
192.09 M
276.94 M
Debt To Equity
0.081
0.15
0.042
0.04
N/A
0.028
0.11
0.045
0.036
0.013
Short Ratio
6.22
8.1
4.52
1.94
2.92
4.08
6.61
3.93
1.39
21.68
Target Price
21.14
37.82
12.0
2.5
37.0
10.67
8.0
5.8
3.0
27.86
Shares Owned By Institutions
86.8
92.37
46.06
86.65
84.04
42.85
59.68
80.89
63.58
96.33
Market Capitalization
1.83 B
1.41 B
91.13 M
44.05 M
2.29 B
81.22 M
69.8 M
83.83 M
83.49 M
579.85 M
Price To Earning
N/A
-3.31
-1.27
N/A
N/A
N/A
N/A
N/A
3.89
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-0.31
N/A
N/A
Price To Sales
874.5
38.08
N/A
411.22
57.2
7.38
N/A
N/A
126.69
N/A
Net Income
(94.9 M)
(180.66 M)
(98.79 M)
(116.8 M)
(160.27 M)
(123.46 M)
(102.06 M)
(68.96 M)
(68.17 M)
(96.66 M)
Earnings Per Share
-1.4
-3.28
-2.86
-2.78
-2.21
-1.7
-1.17
-1.0
-1.23
-2.28
Shares Owned By Insiders
0.46
1.29
8.04
1.84
0.25
10.75
0.49
2.3
10.5
3.67
Revenue
2.07 M
26.98 M
N/A
N/A
12.76 M
N/A
N/A
N/A
9.16 M
N/A
Working Capital
227.18 M
492.33 M
85.31 M
139.95 M
296.89 M
88.06 M
101.62 M
193.38 M
164.46 M
244.89 M
Cash And Equivalents
198.42 M
372.77 M
211.96 M
207.34 M
N/A
178.12 M
239.25 M
277.43 M
192.81 M
240.71 M
Cash Per Share
4.57
12.56
7.05
6.99
N/A
4.77
4.39
6.08
5.32
6.01
Gross Profit
(57.43 M)
(67.15 M)
N/A
1.53 M
N/A
(79.35 M)
N/A
N/A
(48.7 M)
N/A
Day Typical Price
3.86
20.44
2.96
1.25
20.02
1.69
1.08
1.63
1.72
10.2
Accumulation Distribution
0.0809
0.0251
0.0945
0.0547
0.0816
0.0517
0.42
0.0479
0.0345
0.0355
Market Facilitation Index
0.33
0.52
0.29
0.07
1.71
0.09
0.56
0.08
0.06
0.37
Daily Balance Of Power
(1.00)
0.0962
0.4138
0.4286
(0.56)
0.4444
0.8214
0.25
0.6667
1.081081
Period Momentum Indicator
(0.33)
0.05
0.12
0.03
(0.95)
0.04
0.46
0.02
0.04
0.4
Rate Of Daily Change
0.92
1.0
1.04
1.02
0.95
1.02
1.69
1.01
1.02
1.04
Day Median Price
3.92
20.46
2.93
1.25
20.11
1.69
1.05
1.63
1.71
10.24
Price Action Indicator
(0.33)
(0.04)
0.16
0.03
(0.73)
0.005
0.31
N/A
0.04
0.085
Coefficient Of Variation
6981.69
(10,917)
1299.27
(1,650)
994.72
8376.17
922.01
4257.72
(143,366)
(3,855)
Mean Deviation
2.86
2.34
2.73
5.64
2.35
4.44
6.16
1.56
0.9344
2.88
Jensen Alpha
(0.03)
(0.26)
0.1762
(0.88)
0.0742
(0.13)
0.763
(0.03)
(0.08)
(0.41)
Total Risk Alpha
(0.65)
(0.78)
(0.37)
(1.91)
(0.25)
(0.92)
(0.64)
(0.35)
(0.22)
(0.79)
Sortino Ratio
(0.02)
N/A
0.0593
N/A
0.0614
(0.01)
0.1457
(0.03)
N/A
N/A
Downside Variance
11.93
N/A
8.39
N/A
13.5
24.85
50.61
5.96
N/A
N/A
Standard Deviation
4.2
4.38
4.02
8.33
3.61
5.88
10.82
2.39
1.27
4.04
Kurtosis
4.6
27.06
4.23
6.82
7.11
1.02
23.02
3.2
1.23
1.46
Potential Upside
7.92
4.68
7.47
10.0
5.33
12.86
12.07
3.75
1.81
6.17
Treynor Ratio
0.0783
(0.03)
0.3101
(0.18)
0.1616
0.0398
0.3705
0.0808
(0.02)
(0.05)
Maximum Drawdown
23.08
35.92
21.75
61.07
29.23
31.41
32.24
13.98
5.87
19.19
Variance
17.63
19.19
16.15
69.43
13.05
34.53
117.16
5.7
1.6
16.32
Market Risk Adjusted Performance
0.0883
(0.02)
0.3201
(0.17)
0.1716
0.0498
0.3805
0.0908
(0.01)
(0.04)
Risk Adjusted Performance
0.0191
0.0013
0.0669
(0.04)
0.0847
0.0178
0.0922
0.0248
0.0034
(0.01)
Skewness
1.29
4.25
1.61
(1.35)
(0.47)
0.7145
3.89
0.797
0.5065
(0.05)
Semi Deviation
3.26
N/A
2.64
N/A
3.39
4.78
5.91
1.99
N/A
N/A
Information Ratio
(0.02)
(0.04)
0.0427
(0.08)
0.0624
(0.01)
0.0957
(0.03)
(0.11)
(0.06)
Value At Risk
(5.02)
(3.70)
(4.75)
(11.56)
(4.57)
(7.59)
(10.45)
(3.64)
(1.74)
(5.89)
Expected Short fall
(3.56)
N/A
(3.21)
N/A
(2.63)
(5.50)
(7.95)
(1.90)
N/A
N/A
Downside Deviation
3.45
N/A
2.9
N/A
3.67
4.98
7.11
2.44
N/A
N/A
Semi Variance
10.61
N/A
6.98
N/A
11.49
22.82
34.94
3.97
N/A
N/A

Fusion Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Fusion Pharmaceuticals Competition

Fusion Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Fusion Pharmaceuticals in relation to its competition. Fusion Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Fusion Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Fusion Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Fusion Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Fusion Pharmaceuticals position

In addition to having Fusion Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Giant Impact Thematic Idea Now

Giant Impact
Giant Impact Theme
An experimental equal-weighted decomposition of large high potential stocks based on Macroaxis scoring framework. The Giant Impact theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Giant Impact Theme or any other thematic opportunities.
View All  Next Launch
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Consideration for investing in Fusion Stock

If you are still planning to invest in Fusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Fusion Pharmaceuticals' history and understand the potential risks before investing.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Transaction History
View history of all your transactions and understand their impact on performance
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY